Effect of Statins on Risk of Coronary Disease
- 22 December 1999
- journal article
- research article
- Published by American Medical Association (AMA) in JAMA
- Vol. 282 (24) , 2340-2346
- https://doi.org/10.1001/jama.282.24.2340
Abstract
Review from JAMA — Effect of Statins on Risk of Coronary Disease — A Meta-analysis of Randomized Controlled Trials — ContextLowering low-density lipoprotein cholesterol (LDL-C) is known to reduce risk of recurrent coronary heart disease in middle-aged men. However, this effect has been uncertain in elderly people and women.ObjectiveTo estimate the risk reduction of coronary heart disease and total mortality associated with statin drug treatment, particularly in elderly individuals and women.Data SourcesTrials published in English-language journals were retrieved by searching MEDLINE (1966–December 1998), bibliographies, and authors' reference files.Study SelectionStudies in which participants were randomized to statin or control treatment for at least 4 years and clinical disease or death was the primary outcome were included in the meta-analysis (5 of 182 initially identified).Data ExtractionInformation on sample size, study drug duration, type and dosage of statin drug, participant characteristics at baseline, reduction in lipids during intervention, and outcomes was abstracted independently by 2 authors (J.H. and S.V.) using a standardized protocol. Disagreements were resolved by consensus.Data SynthesisData from the 5 trials, with 30,817 participants, were included in this meta-analysis. The mean duration of treatment was 5.4 years. Statin drug treatment was associated with a 20% reduction in total cholesterol, 28% reduction in LDL-C, 13% reduction in triglycerides, and 5% increase in high-density lipoprotein cholesterol. Overall, statin drug treatment reduced risk 31% in major coronary events (95% confidence interval [CI], 26%-36%) and 21% in all-cause mortality (95% CI, 14%-28%). The risk reduction in major coronary events was similar between women (29%; 95% CI, 13%-42%) and men (31%; 95% CI, 26%-35%), and between persons aged at least 65 years (32%; 95% CI, 23%-39%) and persons younger than 65 years (31%; 95% CI, 24%-36%).ConclusionsOur meta-analysis indicates that reduction in LDL-C associated with statin drug treatment decreases the risk of coronary heart disease and all-cause mortality. The risk reduction was similar for men and women and for elderly and middle-aged persons.Keywords
This publication has 18 references indexed in Scilit:
- Effect of Pravastatin on Cardiovascular Events in Women After Myocardial InfarctionThe Endocrinologist, 1999
- Effect of Pravastatin on Cardiovascular Events in Older Patients with Myocardial Infarction and Cholesterol Levels in the Average Range: Results of the Cholesterol and Recurrent Events (CARE) TrialAnnals of Internal Medicine, 1998
- Cholesterol Reduction Yields Clinical BenefitCirculation, 1998
- Cholesterol-Lowering Therapy in Women and Elderly Patients With Myocardial Infarction or Angina PectorisCirculation, 1997
- The Effect of Pravastatin on Coronary Events after Myocardial Infarction in Patients with Average Cholesterol LevelsNew England Journal of Medicine, 1996
- Prevention of Coronary Heart Disease with Pravastatin in Men with HypercholesterolemiaNew England Journal of Medicine, 1995
- Lack of Effect of Lovastatin on Restenosis after Coronary AngioplastyNew England Journal of Medicine, 1994
- Effect of lovastatin on early carotid atherosclerosis and cardiovascular events. Asymptomatic Carotid Artery Progression Study (ACAPS) Research Group.Circulation, 1994
- Efficacy and safety of pravastatin in the long-term treatment of elderly patients with hypercholesterolemiaThe American Journal of Medicine, 1994
- Prevention of restenosis by lovastatin after successful coronary angioplastyAmerican Heart Journal, 1991